Completed PHASE4 INTERVENTIONAL 2-arm NCT00699686

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Effects of Optimized Glycemic Control Achieved With add-on Basal Insulin Therapy on Indexes of Endothelial Damage and Regeneration in Type 2 Diabetic Patients With Macroangiopathy. A Randomized Cross-over Trial Comparing Detemir vs Glargine

Sponsor: University of Padova

Conditions Cardiovascular Disease Endothelial Dysfunction Type 2 Diabetes

Interventions Detemir Glargine

Updated 6 times since 2017 Last updated: Aug 16, 2010 Started: May 31, 2008 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00699686, this PHASE4 trial focuses on Cardiovascular Disease and Endothelial Dysfunction and remains completed. Sponsored by University of Padova, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Padova

Data source: University of Padova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Padua, Italy